Zoetis to acquire Nexvet Veterinary Biologic Therapeutics Co.April 13, 2017Zoetis Inc. announced it will purchase Nexvet Biopharma veterinary biologic therapeutics company for US $6.72 per share, or a valuation of approximately US $85 million. Pending approval, the purchase is expected to be completed during the second half of 2017.
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started